Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Cancer Res ; 81(13): 3480-3494, 2021 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-34127497

RESUMO

Succinate dehydrogenase is a key enzyme in the tricarboxylic acid cycle and the electron transport chain. All four subunits of succinate dehydrogenase are tumor suppressor genes predisposing to paraganglioma, but only mutations in the SDHB subunit are associated with increased risk of metastasis. Here we generated an Sdhd knockout chromaffin cell line and compared it with Sdhb-deficient cells. Both cell types exhibited similar SDH loss of function, metabolic adaptation, and succinate accumulation. In contrast, Sdhb-/- cells showed hallmarks of mesenchymal transition associated with increased DNA hypermethylation and a stronger pseudo-hypoxic phenotype compared with Sdhd-/- cells. Loss of SDHB specifically led to increased oxidative stress associated with dysregulated iron and copper homeostasis in the absence of NRF2 activation. High-dose ascorbate exacerbated the increase in mitochondrial reactive oxygen species, leading to cell death in Sdhb-/- cells. These data establish a mechanism linking oxidative stress to iron homeostasis that specifically occurs in Sdhb-deficient cells and may promote metastasis. They also highlight high-dose ascorbate as a promising therapeutic strategy for SDHB-related cancers. SIGNIFICANCE: Loss of different succinate dehydrogenase subunits can lead to different cell and tumor phenotypes, linking stronger 2-OG-dependent dioxygenases inhibition, iron overload, and ROS accumulation following SDHB mutation.


Assuntos
Ácido Ascórbico/farmacologia , Homeostase , Ferro/metabolismo , Mutação , Estresse Oxidativo , Succinato Desidrogenase/fisiologia , Animais , Antioxidantes/farmacologia , Dioxigenases/antagonistas & inibidores , Feminino , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Mitocôndrias/metabolismo , Mitocôndrias/patologia , Fenótipo , Espécies Reativas de Oxigênio
2.
Cell Rep ; 28(7): 1717-1728.e6, 2019 08 13.
Artigo em Inglês | MEDLINE | ID: mdl-31412242

RESUMO

Nicotinamide adenine dinucleotide (NAD+) is modulated by conditions of metabolic stress and has been reported to decline with aging in preclinical models, but human data are sparse. Nicotinamide riboside (NR) supplementation ameliorates metabolic dysfunction in rodents. We aimed to establish whether oral NR supplementation in aged participants can increase the skeletal muscle NAD+ metabolome and if it can alter muscle mitochondrial bioenergetics. We supplemented 12 aged men with 1 g NR per day for 21 days in a placebo-controlled, randomized, double-blind, crossover trial. Targeted metabolomics showed that NR elevated the muscle NAD+ metabolome, evident by increased nicotinic acid adenine dinucleotide and nicotinamide clearance products. Muscle RNA sequencing revealed NR-mediated downregulation of energy metabolism and mitochondria pathways, without altering mitochondrial bioenergetics. NR also depressed levels of circulating inflammatory cytokines. Our data establish that oral NR is available to aged human muscle and identify anti-inflammatory effects of NR.


Assuntos
Envelhecimento/metabolismo , Anti-Inflamatórios/sangue , Citocinas/sangue , Metaboloma/efeitos dos fármacos , Músculo Esquelético/metabolismo , Niacinamida/análogos & derivados , Transcriptoma/efeitos dos fármacos , Idoso , Idoso de 80 Anos ou mais , Envelhecimento/efeitos dos fármacos , Estudos Transversais , Citocinas/efeitos dos fármacos , Método Duplo-Cego , Humanos , Masculino , Músculo Esquelético/efeitos dos fármacos , NAD/metabolismo , Niacinamida/farmacologia , Compostos de Piridínio
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA